Physician profile
Michael Pimienta
NPI 1114486339
$4,947.18
in general payments reported to CMS, 2019-2025
17 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $164 · 2023: $950 · 2024: $2,059 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,149 · Travel and Lodging: $834 · Grant: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,149.41 |
| Travel and Lodging | $834.14 |
| Grant | $800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $1,419.93 | 2024 | |
| Cook Incorporated | $800.00 | 2023 | |
| 3-D Matrix, INC. | $599.18 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $409.06 | 2023-2025 | Xifaxan, Xifaxan |
| Abbvie INC. | $389.63 | 2024-2025 | |
| Ardelyx, INC. | $277.48 | 2025 | Ibsrela |
| Boston Scientific Corporation | $150.92 | 2022-2025 | Apollo Esg System, Captivator II |
| Eisai INC. | $135.59 | 2022 | |
| Intercept Pharmaceuticals, INC. | $124.83 | 2024 | |
| Mallinckrodt Hospital Products INC. | $123.20 | 2024 | Terlivaz |
| Lilly USA, LLC | $106.60 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $95.91 | 2025 | Voquezna |
| Novo Nordisk INC | $95.05 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $91.55 | 2025 | Rezdiffra |
| Qol Medical, LLC | $78.19 | 2025 | Sucraid |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $35.51 | 2025 | Tremfya |
| Braintree Laboratories, INC. | $14.55 | 2025 | Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pimienta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.